New treatments for acute humoral rejection of kidney allografts

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2007-04-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.16.5.625PMID 17461736
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Comparison of Plasmapheresis Versus High‐Dose IVIG Desensitization in Renal Allograft Recipients with High Levels of Donor Specific Alloantibody

  2006cited by this paper
• The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

  2006cited by this paper
• Epratuzumab in the therapy of oncological and immunological diseases

  2006cited by this paper
• Pharmacodynamics of Rituximab in Kidney Allotransplantation

  2006cited by this paper
• Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy.

  2005cited by this paper
• Protein therapies and antiproliferatives: a new paradigm in immunosuppression☆

  2005cited by this paper
• Ultra‐Late Antibody‐Mediated Rejection 30 Years After a Living‐Related Renal Allograft

  2005cited by this paper
• Humoral Rejection of Organ Allografts

  2005influential reference
• B cell targeted therapies

  2005cited by this paper
• Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation.

  2005influential reference
• ABO Incompatible Kidney Transplantations Without Splenectomy, Using Antigen‐Specific Immunoadsorption and Rituximab

  2005cited by this paper
• Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.

  2005cited by this paper
• Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation.

  2005cited by this paper
• Rituximab Inhibits the In Vivo Primary and Secondary Antibody Response to a Neoantigen, Bacteriophage phiX174

  2005cited by this paper
• Transplanting patients with a positive donor‐specific crossmatch: A single center's perspective

  2004cited by this paper
• Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1

  2004cited by this paper
• Excellent Long‐term Outcome of ABO‐Incompatible Living Donor Kidney Transplantation in Japan

  2004cited by this paper
• Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.

  2004cited by this paper
• Predicting Kidney Graft Failure by HLA Antibodies: a Prospective Trial

  2004cited by this paper
• Successful Renal Transplantation across Simultaneous ABO Incompatible and Positive Crossmatch Barriers

  2004cited by this paper
• Successful Rescue Therapy with Plasmapheresis and Intravenous Immunoglobulin for Acute Humoral Renal Transplant Rejection

  2004cited by this paper
• Rituximab as Treatment for Refractory Kidney Transplant Rejection

  2004cited by this paper
• Consensus Opinion from the Antibody Working Group on the Diagnosis, Reporting, and Risk Assessment for Antibody-Mediated Rejection and Desensitization Protocols

  2004influential reference
• Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection1

  2003influential reference
• Campath‐1H Induction Plus Rapamycin Monotherapy for Renal Transplantation: Results of a Pilot Study

  2003cited by this paper
• Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab

  2003cited by this paper
• Acute Humoral Rejection in Hepatitis C‐Infected Renal Transplant Recipients Receiving Antiviral Therapy

  2003cited by this paper
• Plasmapheresis as rescue therapy in accelerated acute humoral rejection

  2003cited by this paper
• The Addition of Sirolimus to Cyclosporine and Steroids Inhibits the Anti‐Equine Antibody Response in Renal Transplant Recipients Treated with Antithymocyte Globulin

  2003cited by this paper
• Overcoming a Positive Crossmatch in Living‐Donor Kidney Transplantation

  2003cited by this paper
• Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report.

  2002cited by this paper
• Treatment of humoral rejection with rituximab.

  2002cited by this paper
• C4d deposition in acute rejection: an independent long-term prognostic factor.

  2002cited by this paper
• Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury.

  2002cited by this paper
• Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts1

  2002cited by this paper
• Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification.

  2002cited by this paper
• Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy1

  2002cited by this paper
• Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection.

  2001cited by this paper
• C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption.

  2001influential reference
• ACUTE HUMORAL REJECTION IN RENAL ALLOGRAFT RECIPIENTS: I. INCIDENCE, SEROLOGY AND CLINICAL CHARACTERISTICS1

  2001influential reference
• Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch.

  2001cited by this paper
• Rapamycin in transplantation: a review of the evidence.

  2001cited by this paper
• Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody.

  2000cited by this paper
• Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome

  2000cited by this paper
• PLASMAPHERESIS AND INTRAVENOUS IMMUNE GLOBULIN PROVIDES EFFECTIVE RESCUE THERAPY FOR REFRACTORY HUMORAL REJECTION AND ALLOWS KIDNEYS TO BE SUCCESSFULLY TRANSPLANTED INTO CROSS-MATCH-POSITIVE RECIPIENTS

  2000influential reference
• Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates

  2000cited by this paper
• Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries.

  1999cited by this paper
• Mycophenolate mofetil, together with cyclosporin A, prevents anti-OKT3 antibody response in kidney transplant recipients.

  1998cited by this paper
• An association between antibodies specific for endothelial cells and renal transplant failure.

  1998cited by this paper
• Reversal of delayed hyperacute renal allograft rejection with a tacrolimus-based therapeutic regimen.

  1998cited by this paper
• A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine.

  1998cited by this paper
• Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation.

  1998influential reference
• Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action.

  1998influential reference
• Tacrolimus rescue therapy for renal allograft rejection--five-year experience.

  1997cited by this paper
• Complementary data about the inhibitory effects of intravenous immunoglobulins in vitro and in vivo.

  1997cited by this paper
• Pathologic features of acute renal allograft rejection associated with donor-specific antibody, Analysis using the Banff grading schema.

  1996influential reference
• Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin.

  1994cited by this paper
• Capillary deposition of C4d complement fragment and early renal graft loss.

  1993cited by this paper
• Circulating soluble CR1 (CD35). Serum levels in diseases and evidence for its release by human leukocytes.

  1993cited by this paper
• THE SIGNIFICANCE OF THE ANTI–CLASS I RESPONSE

  1992cited by this paper
• Vascular deposition of complement‐split products in kidney allografts with cell‐mediated rejection

  1991cited by this paper
• The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection.

  1990cited by this paper
• Nephrology Dialysis Transplantation Suppression of the Humoral Immune Response by Mycophenolate Mofetil

  year unknowncited by this paper

• Essai de classification des rejets en transplantation rénale

  2023cites this paper
• Therapeutic Apheresis, Immunosuppression and Human Monoclonal Antibodies in Nephrology

  2023cites this paper
• Role of the Immune System in Renal Transplantation, Types of Response, Technical Approaches and Current Challenges

  2022cites this paper
• Acute Anti-A/B Antibody-Mediated Rejection After ABO-Incompatible Kidney Transplantation Treated With Bortezomib and Plasmapheresis: A Case Report.

  2022cites this paper
• Doppler Study of Transplanted Kidney, Follow Up at CKD & Urology Hospital, Dhaka, Bangladesh

  2022cites this paper
• Therapeutic Apheresis and Immunosuppression in Renal Diseases

  2021influential citation
• Recent progress and remaining hurdles toward clinical xenotransplantation

  2021cites this paper
• Infectious complications and graft outcome following treatment of acute antibody-mediated rejection after kidney transplantation: A nationwide cohort study

  2021cites this paper
• Trasplante renal y obtención de órganos bioartificiales

  2021cites this paper
• Therapeutic Apheresis and Immunosuppression in Immunologic Diseases: A Review and Own Observations

  2021influential citation
• Annals of Immunology & Immunotherapy

  2020cites this paper
• Role of ultrasound, Color duplex Doppler and sono-elastography in the evaluation of renal allograft complications

  2019cites this paper
• Therapeutic Apheresis in Immunologic Renal and Neurological Diseases

  2017cites this paper
• Heart Transplantation and Antibody-Mediated Rejection

  2017cites this paper
• Correlation between ultrasound elastography parameters and renal function after kidney transplantation

  2017cites this paper
• Chapter 21 Tolerance in Renal Transplantation

  2017cites this paper
• A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection.

  2017cites this paper
• Efficacy of Combined Plasmapheresis and Intravenous Immunoglobulin Therapy in Kidney Transplant Patients With Chronic Antibody-mediated Rejection.

  2016cites this paper
• ABO Incompatible Kidney Transplantation-A review with a perspective from a center in India

  2016cites this paper
• Plasmaféresis en rechazo agudo del injerto renal mediado por anticuerpos. Estudio realizado en el Hospital Pablo Tobón Uribe, Medellín, Colombia. Año 2005-2015

  2016cites this paper
• One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial

  2016cites this paper
• The Challenge of Acute Antibody-Mediated Rejection in Kidney Transplantation.

  2016cites this paper
• Cell‐mediated and humoral acute vascular rejection and graft loss: A registry study

  2016cites this paper
• The effect of histopathologic and clinical features on allograft survival in renal transplant patients with antibody-mediated rejection

  2016cites this paper
• Essai de classification des rejets en transplantation rénale

  2015cites this paper
• Plasmapheresis in Chronic Active Antibody-Mediated Rejection Kronik Aktif Antikor Aracili Rejeksiyonda Plazmaferez Tedavisi

  2015cites this paper
• Current progress in ABO-incompatible kidney transplantation

  2015cites this paper
• Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association.

  2015cites this paper
• Eculizumab to Treat Antibody-Mediated Rejection in a 7-Year-Old Kidney Transplant Recipient

  2015cites this paper
• Successful treatment of severe acute antibody‐mediated rejection of renal allografts with bortezomib – a report of two pediatric cases

  2015cites this paper
• Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).

  2015cites this paper
• Plasmapheresis in Chronic Active Antibody-Mediated Rejection

  2015cites this paper
• Acute antibody-mediated rejection of the kidney transplant - experience of a single center in Croatia.

  2014cites this paper
• Mechanisms of Allograft Tolerance

  2014cites this paper
• Therapeutic apheresis in nephrology

  2014cites this paper
• Therapeutic apheresis in renal transplantation; current practices

  2014cites this paper
• Antibody-Mediated Rejection in Kidney Transplant Recipients

  2013cites this paper
• Evolving trends in the costs associated with hospital use of immunosuppressive drugs.

  2013cites this paper
• Einfluss von immunsuppressiven Substanzen auf die Funktionen humaner B-Lymphozyten

  2013cites this paper
• Tolerance in Renal Transplantation

  2013cites this paper
• Rethinking the multiple roles of B cells in organ transplantation

  2013cites this paper
• Plasma cell densities and glomerular filtration rates predict renal allograft outcomes following acute rejection

  2012cites this paper
• Successful rescue of refractory acute antibody‐mediated renal allograft rejection with splenectomy – A case report

  2012cites this paper
• Effects of sotrastaurin, mycophenolic acid and everolimus on human B‐lymphocyte function and activation

  2012cites this paper
• Cell Population in Spleens During Antibody-Mediated Rejection: Pathologic and Clinical Findings

  2012cites this paper
• Antibody‐mediated kidney allograft rejection: therapeutic options and their experimental rationale

  2012influential citation
• The Treatment of Acute Antibody-Mediated Rejection in Kidney Transplant Recipients—A Systematic Review

  2012cites this paper
• Risk factors for steroid-resistant T-cell-mediated acute cellular rejection and their effect on kidney graft and patient outcome.

  2012cites this paper
• The B Cell Response to Transplantation Antigens

  2012cites this paper
• ABO – INCOMPATIBLE KIDNEY TRANSPLANTATION – ADVANCES AND CHALLENGES

  2012cites this paper
• ABO Incompatible Kidney Transplantation—Current Status and Uncertainties

  2011cites this paper
• Rapamycin-induced Allograft Tolerance: Elucidating Mechanisms and Biomarker Discovery

  2011cites this paper
• C4d staining in renal allograft biopsies with early acute rejection and subsequent clinical outcome.

  2011cites this paper
• Comparative study for the detection of C4d in paraffin-embedded renal allograft biopsies by immunohistochemical techniques.

  2010cites this paper
• B cells and transplantation tolerance

  2010cites this paper
• A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency

  2010cites this paper
• [Induction treatment by combining immunoglobulins, plasmapheresis and rituximab in hypersensitive patients receiving cadaveric renal allograft].

  2010cites this paper
• Induction of tolerance in renal transplantation using splenic transplantation: experimental study in a canine model.

  2010cites this paper
• Histopathology and Immunophenotype of the Spleen During Acute Antibody‐Mediated Rejection

  2010cites this paper
• The use of original ex vivo immunoadsorption and "multi-manner" apheresis in ABO/H-mismatched kidney transplants--A phase II clinical study.

  2010cites this paper
• Islet Transplantation in Type 1 Diabetics Using an Immunosuppressive Protocol Based on the Anti‐LFA‐1 Antibody Efalizumab

  2010cites this paper
• Adenoviral graft‐nephritis: case report and review of the literature

  2009cites this paper
• Free Bone Graft Attenuates Acute Rejection and in Combination with Cyclosporin A Leads to Indefinite Cardiac Allograft Survival1

  2009cites this paper
• Protein-based Therapies In Experimental And Clinical Transplantation

  2009cites this paper
• Prospects and limitations of post-transplantation alloantibody detection in renal transplantation.

  2009cites this paper
• Rituximab and Intravenous Immunoglobulin Treatment of Chronic Antibody-Mediated Kidney Allograft Rejection

  2009cites this paper
• [New faces of acute rejection in 2008].

  2009cites this paper
• Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.

  2008cites this paper
• Successful therapy with rituximab of refractory acute humoral renal transplant rejection: a case report.

  2008cites this paper
• Immunologie de la transplantation : rejets et infections en transplantation d’organes solides

  2008cites this paper
• A case of desensitization, transplantation, and allograft dysfunction.

  2008cites this paper
• Costimulation targeting therapies in organ transplantation

  2008cites this paper
• "To B or not to B?" B-cells and graft rejection.

  2008cites this paper
• Allogeneic islet transplantation

  2007cites this paper
• Synthèse et évaluation pharmacologique d'imidazolidin-2-ones et d'analogues à potentialités immunosuppressives

  2007cites this paper
• Rejets aigus humoraux

  2006cites this paper
• Aha Scientific Statement Antibody-mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management a Scientific Statement from the American Heart Association Endorsed by the International Society for Heart and Lung Transplantation

  year unknowncites this paper